Peptide CDMOs in Europe: 24 compared (2026)
24 of the 255 contract development and manufacturing organisations in A4BEE’s European census list peptide manufacturing among their capabilities. The largest, with revenue over €1bn, are Almac Group, Olon, Pharmathen and Seqens. 11 sit between €250m and €1bn and 9 are smaller or niche.
By ownership: 8 family-owned, 6 private equity, 5 listed and 5 part of a pharma or industrial group. They are spread across 12 countries, led by Italy (5), France (3), Switzerland (3), the United Kingdom (3) and Belgium (2). 16 of the 24 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
24 companies
Peptide CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| Almac Group£400 m+ capex program; broad clinical + diagnostics services alongside API. | Craigavon, United Kingdom | Family-ownedMcClay charitable trust | Tier 1 | £1.027 bn FY2024 | Small-molecule API, Peptide, Antibody-drug conjugate (ADC) | high |
| OlonOne of Europe's largest API CDMOs; absorbed Euticals. Chemical synthesis + microbial fermentation, HPAPI, ADC bioconjugation. | Rodano, Italy | Family-owned | Tier 1 | ~€546 m (2024, group) | Small-molecule API, Microbial and protein, Peptide, Antibody-drug conjugate (ADC), Biologics and biosimilars | high |
| PharmathenVertically integrated developer of complex drug-delivery tech offering CDMO/co-development: long-acting injectables, SR oral solids, ophthalmics. | Pallini, Greece | Private equityPartners Group | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish, Peptide | high |
| SeqensLarge API/small-molecule CDMO plus specialty ingredients; ~200 APIs. Revenue includes non-pharma specialty ingredients. | Écully, France | Private equitySK Capital | Tier 1 | ~€1.1 bn (group) | Small-molecule API, Peptide | high |
| Ajinomoto Bio-Pharma (OmniChem)Small-molecule API CDMO: HPAPIs, ADC conjugation, oligonucleotides, continuous-flow chemistry. | Wetteren, Belgium | Part of a pharma or industrial groupAjinomoto | Tier 2 | not disclosed | Small-molecule API, Peptide, Antibody-drug conjugate (ADC) | high |
| BachemSIX-listed peptide & oligonucleotide CDMO; largest independent peptide maker. | Bubendorf, Switzerland | Listed | Tier 2 | CHF 605.3 m (2024) | Peptide, Small-molecule API | high |
| CambrexSmall-molecule API + continuous flow + liquid-phase peptides; several EU sites. | East Rutherford, NJ, United States | Private equityPermira | Tier 2 | ~US$500 m–1 bn | Small-molecule API, Peptide | medium |
| ChemiCustom/contract API manufacturing plus complex generics and proprietary peptides, low-molecular-weight heparins. | Cinisello Balsamo, Italy | Part of a pharma or industrial groupItalfarmaco Group | Tier 2 | not disclosed | Small-molecule API, Peptide, Biologics and biosimilars | high |
| CordenPharmaPeptide + lipid/LNP specialist riding the GLP-1 boom (e.g. Viking deal). | Basel, Switzerland | Private equity | Tier 2 | ~US$530 m | Peptide, mRNA and LNP, Sterile fill-finish, Small-molecule API | medium |
| EUROAPIEuronext Paris; Sanofi ~30% + Bpifrance. ~200 small-molecule APIs plus peptides and oligos. | Paris, France | Listed | Tier 2 | €911.9 m (2024), −10% | Small-molecule API, Peptide | low |
| Evonik Health CareDrug-substance CDMO for complex APIs, HPAPIs and pharmaceutical lipids (LNP/RNA delivery). | Essen, Germany | ListedEvonik Industries | Tier 2 | not disclosed | Small-molecule API, Peptide | low |
| FlammaFamily-owned small-molecule API CDMO since 1950; leader in amino acids and peptide building blocks. FDA-inspected. | Chignolo d'Isola, Italy | Family-ownedNegrisoli family | Tier 2 | not disclosed | Small-molecule API, Peptide | high |
| Haupt Pharma LatinaAenova Group's designated central sterile site. Third-party sterile fill-finish plus beta-lactam injectables and oral solids. | Latina, Italy | Part of a pharma or industrial groupAenova Group | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose, Monoclonal antibody, Peptide, Biologics and biosimilars | low |
| PolyPeptide GroupSIX-listed independent CDMO for peptide & oligonucleotide APIs. | Baar, Switzerland | Listed | Tier 2 | ~€336 m (2024) | Peptide | high |
| Quotient SciencesFull-service third-party CDMO (drug substance/product + clinical). UK-HQ under European PE. | Nottingham, United Kingdom | Private equityPermira | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Peptide, Sterile fill-finish | low |
| Aspen OssBiochemical/chemical API CDMO: steroid hormones, heparin, peptides, alkaloids. Former Organon/Merck site. | Oss, Netherlands | ListedAspen Pharmacare | Tier 3 | not disclosed | Small-molecule API, Peptide | high |
| GalenicaPrivately owned Swedish CDMO (est. 1999); dev + GMP manufacture of solids, liquids, semi-solids, small molecules and peptides incl. high-potency. | Malmö, Sweden | Family-owned | Tier 3 | not disclosed | Oral solid dose, Peptide, Small-molecule API | high |
| GP PharmCDMO focused on highly complex injectables: peptides, oligonucleotides, hormones, liposomes and microspheres. FDA-inspected. | Sant Quintí de Mediona, Spain | Family-ownedParente family | Tier 3 | not disclosed | Peptide, Sterile fill-finish | high |
| IBI LorenziniAseptic manufacturing of sterile injectables (specialist in sterile penicillins/cephalosporins) plus oral, topical and biotech. | Aprilia, Italy | Family-ownedIbigen Group | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Monoclonal antibody, Peptide | high |
| InnoCore PharmaceuticalsDrug-delivery CDMO for long-acting injectables (microspheres, implants, depot gels) via proprietary SynBiosys polymers. | Groningen, Netherlands | Family-owned | Tier 3 | not disclosed | Peptide, Biologics and biosimilars, Sterile fill-finish | high |
| Kaneka EurogentecBiologics CDMO: microbial proteins, GMP plasmid DNA, oligonucleotides, peptides; added GMP mRNA (made a COVID vaccine). | Seraing, Belgium | Part of a pharma or industrial groupKaneka | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, mRNA and LNP, Peptide | high |
| Paras BiopharmaceuticalsFounder-led microbial-biologics CDMO: recombinant biologics/biosimilars in microbial systems, plus peptides and proteins. Scales 10L→750L+. | Oulu, Finland | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, Peptide | medium |
| PMC IsochemCustom API and peptide CDMO. Acquired by PMC Group (US) in 2017. | Vert-le-Petit, France | Part of a pharma or industrial groupPMC Group | Tier 3 | not disclosed | Small-molecule API, Peptide | high |
| Sterling Pharma | Cramlington, United Kingdom | Private equityGHO Capital | Tier 3 | ~£130 m FY2023 | Small-molecule API, Antibody-drug conjugate (ADC), Peptide | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe